Leica Biosystems Receives FDA Approval for Aperio GT 450 DX Digital Pathology System

Leica Biosystems has received US FDA 510(k) clearance of its flagship Aperio GT 450 DX digital pathology system, a proven technology that delivers consistently high quality images with a fast turnaround time of < 32 seconds/slide.

There has never been a better time for laboratories to optimize their workflow with digital pathology, enabling clinicians to maintain a high standard of quality with world-class images and fast turnaround times for the best possible patient care,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems, a company with 25 years of experience in implementing, integrating and innovating in the field of digital pathology.

en_GBEnglish (UK)